A recent meta-analysis reported that next to bariatric surgery, treatment with a single PPAR-γ agonist (pioglitazone) was most effective in patients with NASH for steatosis and reduction of lobular inflammation [24]. The gene discussed is PPARG; the disease is metabolic dysfunction-associated steatohepatitis.